NCT05116826View on ClinicalTrials.gov

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

November 5, 2021

Primary Completion Date

April 8, 2022

Study Completion Date

April 13, 2022

Conditions

Moderate Hepatic ImpairmentSevere Hepatic ImpairmentLiver Diseases

Interventions

DRUG

Nitazoxanide

500 mg Twice Daily for 7 days

Trial Locations (2)

32802

Orlando Clinical Research Center, Orlando

33014

Panax Clinical Research, Miami Lakes

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Genfit

INDUSTRY

NCT05116826 - Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients | Biotech Hunter | Biotech Hunter